Skip to main content

Pharma/Regulatory

Dr. John Cush
@RheumNow
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
anita
@docdhanrajani
@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Eli Lilly and Company. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 annual meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Sadhak Sengupta
@sadhaksengupta
@Aclockworkolive @drdavidliew @NEJM @RheumNow Both rap-cel and zola-cel targets to keep the infusion material enriched in CCR7+CD27+ naive state, for which the ex vivo part of the expansion has to be stopped before the cells start differentiating. Longer the ex vivo culture, higher the percentage of differentiation.
Dr. John Cush
@RheumNow
RheumNow’s expanded #ACR26 annual meeting coverage is sponsored by UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Janet Pope
@Janetbirdope
#Steroid sparing in #ANCA #vasculitis w #Iptacopan #RCT interim + results Obvious #GC lower does on iptacopan A complement B inhibitor C3bBb Elephant in room 🐘 ?rare side effects of liver and bile duct like #avacopan #LB16 #ACR26 @ACRheum @RheumNow https://t.co/nEoZlgsMZQ
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of #ACR26 Annual Meeting is sponsored by Eli Lilly and Company . All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
@RheumNow
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Eli Lilly and company. All coverage content is independently selected by RheumNow and its faculty.
Adela Castro
@AdelaCastro222

CAR-T in SLE 2026 -Autologous CART: likely to achieve target faster (shorter time for SLEDAI/DORIS) -CD19-vs dual target (BCMA): no significant difference on SLEDAI -Pt w/ LN at baseline had steeper decline on SLEDAI -SAFETY: 64% of pts had CRS manageable (low grade) 95% of https://t.co/XyMOeoSpPL

×